MarketPulse

GLP-1/GIP agonist

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics' Billion-Dollar Bet: Can VK2735 Compete in the Weight-Loss Gold Rush?

Viking Therapeutics' VK2735 targets the $100+ billion weight-loss market. Success could drive massive stock appreciation, but clinical and competitive risks remain substantial.
LLYVKTXbiotechregulatory approval
BenzingaBenzinga··Vandana Singh

Viking Therapeutics Climbs on Competitive Positioning in Obesity Drug Race

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.
LLYNVORHHBYVKTXPhase 3 trialsweight loss